Fertility Market in the US 2016-2020
Outlook of the fertility market in the US
Technavio’s market research analyst predicts the fertility market in the US to grow at steadily a CAGR of around 4% by 2020. The fertility market in the US consists of fertility drugs and assisted reproductive technology (ART) services segments. Increasing fertility issues among the aging population, rising disposable income, growing adoption of fertility services by homosexual couples, and augmented support from the US federal government are some of the major factors that will impel growth in this market during the forecast period.
Cultural shifts in the US will also have a positive impact on the market growth. Recently, it has been observed that there is an increase in the number of same-sex parents in the US. According to Child Welfare, it was estimated that during 2012, up to 6 million children in the US were parented by same-sex parents. In this market study, analysts have predicted that the number of women in same-sex relationships using donor sperm have risen from 15% (before same-sex marriage) to 20% after regulatory changes for same-sex marriage. This growing social acceptance of same-sex marriages will indirectly aid in the growth of this market during the predicted period.
Segmentation by treatment type and analysis of the fertility market in the US
- Infertility drugs
At present, the ART segment leads the market and accounts for approximately 67% of the total market share. This segment includes in-vitro fertilization and other treatment options like intrauterine insemination, reproductive surgery, and surrogacy. In-vitro fertilization (IVF) accounts for around 99% of all the ART treatments. Since IVF is one of the most popular assisted fertility techniques, its augmented adoption due to its enhanced rate of success will result in the strong growth of this market segment during the predicted period.
Competitive landscape and key vendors
The fertility market in the US is highly fragmented due to the presence of many well-established vendors. The competitive scenario in this market is propelled by M&A and investments in R&D activities for the development of novel products. Since this market has low entry barriers, a number of players are expected to enter the market because of its high revenue generating potential. Furthermore, the consolidation of pharmaceutical companies will bolster the production of fertility drugs, which in turn will lead to market growth.
Leading vendors in the market are -
- Ferring Pharmaceuticals
Other prominent vendors in the market include Abbott Laboratories, AbbVie, Actavis, Apricus Biosciences, AstraZeneca, Auxogyn, Bristol-Myers Squibb, Elelixis Diagnostics, Eli Lilly, EMD Serono, IKS International, In Vitro Care, Invo Bioscience, Irvine Scientific, IVFtech Aps, Life Global, Medical Electronic Systems, Meditex, Novartis, Ovascience, Pantec Biosolutions, Pfizer, Sanofi, Vivus, and Xytex Cryo International.
Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the fertility market in the US?
- What are the key market trends impacting the growth of the fertility market in the US?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the vendors in the fertility market in the US?
- What are the key outcomes of the five forces analysis of the fertility market in the US?